Mechanism
Zepbound contains tirzepatide and works through GIP plus GLP-1 pathways, while Wegovy contains semaglutide and works through GLP-1 alone.
Zepbound and Wegovy injections are once-weekly obesity treatments. Zepbound contains tirzepatide, which acts on GIP and GLP-1 receptors; Wegovy contains semaglutide, which acts on GLP-1 receptors. Wegovy tablets are taken daily. SURMOUNT-5 compared injected Zepbound with injected Wegovy at 1.7 mg or 2.4 mg, not oral Wegovy or Wegovy HD. Average weight loss was greater with Zepbound at 72 weeks in that study. The choice still depends on eligibility, coverage, tolerability and the person’s current treatment.
Lilly publishes different savings and self-pay paths depending on insurance status. Commercially insured patients and self-pay patients can see very different pricing rules, while government beneficiaries often follow a separate access path. Program terms can change, so the workflow matters more than any one static number copied off the internet.
Tirzepatide activates GIP and GLP-1 receptors. Semaglutide activates GLP-1 receptors. Trials use specified populations, doses, and durations. Comparing percentages from unrelated trials can be misleading.
Tirzepatide and semaglutide are different treatments, and their brands have different indications. A useful comparison considers your diagnosis, treatment response, side effects, administration, and ability to continue care. A larger average trial result does not make one medicine right for everyone.
Both have adult obesity-treatment options under the appropriate brand and criteria. Diabetes, pediatric, cardiovascular, OSA, and MASH indications differ. Review the exact label instead of transferring an indication between brands.
Review what you have already taken, dose and duration, side effects, nutrition, glucose when relevant, and access. A plateau needs assessment before switching. The prescriber sets a transition and titration plan. Do not overlap treatments or convert milligrams yourself.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs an emergency department assessment now. Call 911 for severe breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Do not wait for a nutrition visit. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Tirzepatide has oral-contraceptive precautions after starting and increasing. Semaglutide has a two-month planned-pregnancy interval for weight treatment. These details can change the choice.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
In SURMOUNT-5, adults with obesity without diabetes had greater average weight reduction with the studied tirzepatide regimen than the studied semaglutide regimen over 72 weeks. The trial used specific maximum tolerated doses and was funded by Lilly. It does not predict your result or compare every current dose, tablet, or indication.
A switch needs review of the exact product, dose, time on treatment, response, side effects, nutrition, and access. A plateau alone does not mean you must change medicines. The prescriber sets a transition and titration plan. Do not overlap products or convert milligrams yourself.
Discuss the comparison with the prescribing clinician using your actual diagnosis, prior dose, response, side effects, pregnancy plans, and coverage. The next step is an individualized decision and transition plan if needed, not an automatic switch based on a trial average.
Zepbound contains tirzepatide and works through GIP plus GLP-1 pathways, while Wegovy contains semaglutide and works through GLP-1 alone.
Lilly's SURMOUNT-5 results reported average weight loss of 20.2% with Zepbound versus 13.7% with Wegovy at 72 weeks, but patients still need a real fit decision rather than a headline alone.
The more effective medication on paper is not always the easier medication to start, cover, or refill. Coverage rules and pharmacy stability can change the practical winner.
Patients who are already doing well on Wegovy, have better Wegovy coverage, or want the plan with less change may not need to switch just because Zepbound trends stronger on average.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods.
View weight-loss location Get directions
Queens
37-15 23rd Ave, Astoria, NY 11105
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods.
View weight-loss location Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods.
View weight-loss location Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A Brooklyn access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods.
View weight-loss location Get directions
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A Long Island access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities.
View weight-loss location Get directions
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods.
View weight-loss location Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods.
View weight-loss location Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods.
View weight-loss location Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities.
View weight-loss location Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods.
View weight-loss location Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods.
View weight-loss location Get directions
Arrange an evaluation to discuss suitable care, preparation and follow-up with a clinician.
Open main Zepbound overview